

AD \_\_\_\_\_

Award Number: DAMD17-01-1-0665

TITLE: Blocking Internalization of Phosphatidylethanolamine at  
Cleavage Furrow of Mitosis as a Novel Mechanism of  
Anti-Breast-Cancer Strategy

PRINCIPAL INVESTIGATOR: Zheng Cui, M.D.

CONTRACTING ORGANIZATION: Wake Forest University School of  
Medicine  
Winston-Salem, North Carolina 27157

REPORT DATE: June 2003

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are  
those of the author(s) and should not be construed as an official  
Department of the Army position, policy or decision unless so  
designated by other documentation.

20031017 041

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY</b> (Leave blank)		<b>2. REPORT DATE</b> June 2003	<b>3. REPORT TYPE AND DATES COVERED</b> Final (1 Jun 2001 - 31 May 2003)	
<b>4. TITLE AND SUBTITLE</b> Blocking Internalization of Phosphatidylethanolamine at Cleavage Furrow of Mitosis as a Novel Mechanism of Anti-Breast-Cancer Strategy			<b>5. FUNDING NUMBERS</b> DAMD17-01-1-0665	
<b>6. AUTHOR(S)</b> Zheng Cui, M.D.				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Wake Forest University School of Medicine Winston-Salem, North Carolina 27157  E-Mail: zhengcui@wfubmc.edu			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited				<b>12b. DISTRIBUTION CODE</b>
<b>13. ABSTRACT (Maximum 200 Words)</b> <p>During the formation of cleavage furrow of mitosis, phosphatidylethanolamine (PE) flips from inner leaflet of the plasma membrane to the outer leaflet specifically in the furrow region near the contractile ring. Immediately after the contractile ring separates the two daughter cells, PE returns from outer leaflet to inner leaflet. This transient movement of PE during cytokinesis is essential because blockage of this PE movement results in a failure of mitosis and leads to cell death. Cinnamycin produced by <i>Streptoverticillium griseoverticillatum</i> targets specifically to PE on cell surface at the cleavage furrow of mitotic cells but not the non-dividing cells. This proposal is to test if cinnamycin is a better anti-tumor drug for treatment of breast cancers because of several advantages: 1) Cinnamycin only targets proliferating cells but has no effect on non-proliferating cells. 2) The anti-proliferation activity doesn't require cinnamycin to enter the cells. 3) Cinnamycin doesn't have to suffer the effect of multi-drug resistance mechanism or cellular metabolism. Because cinnamycin is no longer available commercially, we had to devise production procedures and to purify this compound in our own lab. Thus, completion of this proposal would require longer time than that was originally proposed.</p>				
<b>14. SUBJECT TERMS</b> Breast cancer; cinnamycin, anti-cancer therapy, mouse model				<b>15. NUMBER OF PAGES</b> 4
				<b>16. PRICE CODE</b>
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

## Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	4
Reportable Outcomes.....	4
Conclusions.....	4
References.....	n/a
Appendices.....	n/a

## Final Report

### Introduction.....

During the formation of cleavage furrow of mitosis, phosphatidylethanolamine (PE) flips from inner leaflet of the plasma membrane to the outer leaflet specifically in the furrow region near the contractile ring. Immediately after the contractile ring separates the two daughter cells, PE returns from outer leaflet to inner leaflet. This transient movement of PE during cytokinesis is essential because blockage of this PE movement results in a failure of mitosis and leads to cell death. Cinnamycin produced by *Streptovercillium griseovercillatum* targets specifically to PE on cell surface at the cleavage furrow of mitotic cells but not the non-dividing cells. This proposal is to test if cinnamycin is a better anti-tumor drug for treatment of mammary cancer models in mice.

### Body.....

Because cinnamycin is no longer available commercially, we had to devise production procedures and to purify this compound in our own lab. Thus, completion of this proposal would require longer time than that was originally proposed. In the initial funding period, we have performed extensive literature search for commercial source of cinnamycin suppliers. However, none of the previous suppliers continues to sell this compound. We proceeded to contact several academic investigators who have published using this compound. All these investigators have stopped to use this compound and no longer have it in their possession. Thus we have decided to produce and purify this compound in our own lab.

### Key Research Accomplishments.....

During the residual funding period since last report, we have attempted to produce and isolate cinnamycin from cell culture of bacterium *Streptovercillium griseovercillatum*.

### Reportable Outcomes.....

None.

### Conclusions.....

Cinnamycin is an old compound that is no longer produced by any commercial source or by academic entity. Thus our goal to test its anti-breast cancer effect could not be performed as we originally planned. The emphasis then changed to production of cinnamycin in our own lab. Although several attempts were made to purify the peptide, we were not able to isolate enough peptide to perform any test in cell culture experiment and animal experiments in the proposed budget and time frame. However, we will continue to isolate cinnamycin in our lab as well as to search collaboration partners who had experience in isolation of the peptide even after this funding is over. Once enough cinnamycin is obtained, we will seek other funding resources to perform tests in animals.

### References.....

None.

### Appendices.....

None